CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02202746
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:40.563041+00:00
Published At: 2020-06-23T00:00:00+00:00
Record Updated At: 2020-06-23
Results Posted At: 2020-06-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Breast Cancer", "Metastatic Breast Cancer", "MBC", "HER2 Positive", "HER2", "Estrogen Receptor Positive", "ER", "Triple Negative"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-06-23"
protocolSection.identificationModule.nctId: "NCT02202746"
protocolSection.identificationModule.officialTitle: "A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-06-23"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.